Skip to main content
TipRanks
Go Ultimate75% OFF

Amneal Pharmaceuticals (2DT) Stock Price & Analysis

2 Followers

2DT Stock Chart & Stats

€19.30€0.60(3.21%)
At close: 5:30 PM GMT+1
€14.4€14.6Jun 12Aug 31
Day’s Range
EUR 19.30 - EUR 19.40
52-Week Range
EUR 9.80 - EUR 19.40
Previous Close
EUR 18.70
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 6.79B
Enterprise Value
EUR 9.98B
Total Cash (Recent Filing)
EUR 157.40M
Total Debt (Recent Filing)
EUR 3.28B
Price to Earnings (P/E)
49.1
Beta
0.65
Next Earnings
Feb 26, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Diversified, Integrated Pharmaceutical Model

A multi-segment portfolio gives Amneal several revenue engines across volume-driven generics, branded therapies and biosimilars. Its integrated development and manufacturing capabilities can support product control, commercialization breadth and a more durable platform for launching medicines across markets.

Improving Growth And Profitability

The recovery from losses to positive TTM earnings, alongside revenue growth and stronger gross margins, indicates meaningful operating progress. If sustained, improved profitability can strengthen internal funding capacity and provide a more resilient base for continued investment in launches and capabilities.

Biosimilar Platform And Pipeline

The Kashiv combination adds research, clinical, regulatory, manufacturing and commercialization capabilities to Amneal’s biosimilar strategy. This integrated platform, paired with multiple planned launches and broad biologic exclusivity opportunities, supports a potentially durable growth avenue through the next several years.

Bears Say

High Balance-sheet Leverage

Amneal’s debt-heavy capital structure leaves less financial flexibility if operating performance weakens or integration takes longer than expected. High leverage can also constrain investment choices and make interest, refinancing and acquisition-related obligations more important to the company’s long-term execution.

Weaker Recent Cash Conversion

The recent decline in operating and free cash flow means accounting profitability is not currently translating into cash at the same rate as in prior years. Persistently weaker conversion would reduce funds available for debt reduction, capacity expansion and other strategic investments.

Modest And Historically Volatile Earnings Quality

Although profitability has improved, the relatively modest net margin leaves limited room for product, pricing or cost pressures before earnings are affected. Historical volatility also makes it harder to establish that the latest profit recovery will persist across future product and operating cycles.

Amneal Pharmaceuticals News

2DT FAQ

What was Amneal Pharmaceuticals’s price range in the past 12 months?
Amneal Pharmaceuticals lowest stock price was €9.80 and its highest was €19.40 in the past 12 months.
What is Amneal Pharmaceuticals’s market cap?
Amneal Pharmaceuticals’s market cap is €6.79B.
When is Amneal Pharmaceuticals’s upcoming earnings report date?
Amneal Pharmaceuticals’s next earnings report is estimated for Feb 26, 2027 (not yet confirmed), which is in 97 days.
How were Amneal Pharmaceuticals’s earnings last quarter?
Amneal Pharmaceuticals released its earnings results on Nov 03, 2026. The company reported €0.232 earnings per share for the quarter, beating the consensus estimate of €0.211 by €0.021.
Is Amneal Pharmaceuticals overvalued?
According to Wall Street analysts Amneal Pharmaceuticals’s price is currently Undervalued.
Does Amneal Pharmaceuticals pay dividends?
Amneal Pharmaceuticals does not currently pay dividends.
What is Amneal Pharmaceuticals’s EPS estimate?
Amneal Pharmaceuticals’s EPS estimate is 0.21.
How many shares outstanding does Amneal Pharmaceuticals have?
Amneal Pharmaceuticals has 348,412,720 shares outstanding.
What happened to Amneal Pharmaceuticals’s price movement after its last earnings report?
Amneal Pharmaceuticals reported an EPS of €0.232 in its last earnings report, beating expectations of €0.211. Following the earnings report the stock price went down -6.349%.
Which hedge fund is a major shareholder of Amneal Pharmaceuticals?
Hedge funds hold Amneal Pharmaceuticals shares: the largest hedge-fund position in Amneal Pharmaceuticals is 1,619,564,056 shares, and hedge funds increased their holdings by 24.0K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology